Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

41.41 -0.63 (-1.51%)
Streaming Delayed Price Updated: 2:51 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
29 30 Next >
Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover?
Roche hoped to prevent Alzheimer's disease in patients with a genetic defect. 
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
Via Benzinga
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
From Genentech
Via Business Wire
5 Cash-Cow Stocks to Buy for a Turbulent Market
These are five of the best cash-cow stocks and ETFs to buy that could help grow your investment portfolio in the second half of 2022 
Via InvestorPlace
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
From Genentech
Via Business Wire
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Via Benzinga
Diagnostic Companies Focus On Monkeypox Tests Following Outbreak; Experts Do Not Count It As Next COVID Yet
Diagnostic companies aggressively developed tests for monkeypox as governments struggle to trace the world's first major viral infection outbreak beyond Africa, 
Via Benzinga
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
From Genentech
Via Business Wire
One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market
Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public... 
Via Benzinga
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
From Genentech
Via Business Wire
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
Via Benzinga
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
Via Benzinga
Current Report: Roche Holding
Roche’s price per share was $39.75 as of Friday's market close. One year ago its price was $42.20. 
Via Talk Markets
The OTC Markets' Most Active Securities Welcomes New Names And Experiences A Reshuffle In April
Photo by Becca on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. First-quarter 2022 market... 
Via Benzinga
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Roche isn't the only company working on an anti-TIGIT molecule. 
Via Investor's Business Daily
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung... 
Via Benzinga
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Market Selloff
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
Roche Releases More Evrysdi Data For Very Young Infants With SMA
Via Benzinga
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
Via Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine. 
Via Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
Via Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.